COMMUNIQUÉS West-GlobeNewswire

Active Biotech AB Year-end report January - December 2017
15/02/2018
Fourth quarter in brief The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS Patent regarding tasquinimod for the treatment of acute leukemia granted in Europe The process [...]
Dow BioMedica to distribute Biohit GastroPanel® in Korea
15/02/2018
Biohit Oyj Press release, 15 th February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for [...]
Ossur Hf : Annual General Meeting 8 March 2018
15/02/2018
Announcement no. 10/2018 Reykjavik, 15 February 2018 Össur hf. - Annual General Meeting 8 March 2018 Össur hf.'s Annual General Meeting will be held on Thursday, 8 March 2018, at 9:00 am (GMT) at the Company's offices [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
15/02/2018
REGULATED INFORMATION GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Navamedic ASA: Q4 2017 results
15/02/2018
Oslo, February 15, 2018 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 45.2 million in the fourth quarter of 2017, down from NOK 81.6 million in the same period in 2016, following the planned discontinuation of [...]
VALNEVA Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
15/02/2018
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of €109.8 million in 2017 (2016 - €97.9 million) representing year-on-year [...]
Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits
15/02/2018
Valneva publie un très bon chiffre d'affaires 2017 soutenu par une croissance à deux chiffres des ventes de produits Forte croissance des ventes en 2017 (chiffres non audités) Chiffre d'affaires total de €109,8 millions [...]
Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors
15/02/2018
Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]
Targovax ASA: Fourth quarter and full year 2017 results
15/02/2018
Oslo, Norway, 15 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its third quarter 2017 results. A meeting for [...]
Addex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors
15/02/2018
Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of [...]
MDxHealth Notice of Financial Year 2017 Results
15/02/2018
COMPANY ANNOUNCEMENT REGULATED INFORMATION INSIDE INFORMATION MDxHealth Notice of Financial Year 2017 Results Conference call for analysts and investors to be held on 22 February 2018 at 15:00 CET IRVINE, CA, and [...]
Avis de publication des résultats financiers de MDxHealth pour l'exercice 2017
15/02/2018
ANNONCE D'ENTREPRISE INFORMATIONREGLEMENTAIRE INFORMATION PRIVILEGIEE Avis de publication des résultats financiers de MDxHealth pour l'exercice 2017 Une conférence téléphonique pour les analystes et les investisseurs [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
15/02/2018
REGULATED INFORMATION GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases
15/02/2018
Pratteln, Switzerland, February 15, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into a license agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human [...]
Arbutus Enters Exclusivity Agreement with Roivant Sciences
15/02/2018
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced [...]
Bradmer Pharmaceuticals Announces Closing of Private Placement of Subscription Receipts and Signing of Arrangement Agreement in Connection With Proposed Business Combination Between Bradmer, Galaxy Digital and First Coin
15/02/2018
Private placement raises gross proceeds of approximately C$305 million to solidify Galaxy Digital’s dedicated blockchain and cryptocurrency merchant banking platform NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR [...]
Antares Pharma Announces FDA Approval of Partner’s Product Utilizing Our QuickShot Auto Injector
15/02/2018
EWING, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals ( [...]
AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
15/02/2018
WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) today announced that the U.S. Food and Drug Administration (FDA) approved the Makena® subcutaneous auto-injector drug-device [...]
TearLab Provides Updates on Its Osmolarity Test and TearLab Discovery™ Platform
14/02/2018
SAN DIEGO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced its plans to appeal a recent ruling from the Federal Court of Canada related to its [...]

Pages